Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said the agency’s new risk-based COVID-19 vaccine framework contradicts the ...

Drug services provider Medtide (3880.HK) is looking to raise HK$514 million (410 million yuan or $65.48 million) in a listing ...

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, ...

From the column: "Artificial Intelligence, or AI, ... can and must transform how we monitor, analyze, and respond to border ...

Unfortunately for shareholders, while the Global Industrial Company (NYSE:GIC) share price is up 37% in the last five years, that's less than the market return. The last year has been disappointing, ...

Novartis AG offers growth potential with a balanced drug portfolio, manageable debt, and shares priced below fair value.

Ten people have been effectively cured of their type 1 diabetes after a breakthrough infusion of a new treatment on the path ...

Buying Dividend Aristocrats at bargain prices can be a winning investment strategy. Read about two such stocks that are ...

NEW YORK/MELBOURNE - Incannex Healthcare Inc. (NASDAQ:IXHL) has appointed Douglas B. Kirsch, M.D., to its Clinical Advisory Board for IHL-42X, the company’s investigational trea ...